March 17, 2023
Economic Outcomes
CGM Best PracticesInterview

Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute

Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM

Share:

March 2, 2023
Coverage and Benefit Design
Guidelines / Policy

The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin and those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS will enact expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.

Learn More
Share:

March 2, 2023
Population Health
CE Activities

Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)

Expiration Date:  August 31, 2024

Click here to begin!

Educational Objectives
After completing this activity, the participant should be better able to:

  • Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
  • Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
  • Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes

Expert Faculty

Richard Dlott, MD

Managing Director

FourthFlight

Jeffrey Dunn, PharmD, MBA

Chief Clinical Officer

Cooperative Benefits Group

Jointly provided by Impact Education, LLC, and Medical Education Resources.
This activity is supported by an independent educational grant from Dexcom, Inc.

Share:

February 17, 2023
CGM Technology and Digital Health
CGM InnovationsWebinar / Archive

Click here to download the summary from this live event.

Share:

February 16, 2023
Population Health
CE Activities

Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)

Expiration Date:  June 30, 2024

Click here to begin!

Educational Objectives
After completing this activity, the participant should be better able to:

  • Describe the risks of hypoglycemia in older patients with diabetes
  • Access health plan opportunities to identify underserved populations with diabetes, address the risks of hypoglycemia, and to implement appropriate interventions for prevention of hypoglycemia in high-risk populations
  • Identify steps for the delivery of successful quality improvement interventions in diabetes and the role of real-time continuous glucose monitoring

Expert Faculty

Estay Greene, PharmD, MBA

Vice President of Pharmacy

Zing Health

Jeffrey Dunn, PharmD, MBA

Chief Clinical Officer

Cooperative Benefits Group

Jointly provided by Impact Education, LLC, and Medical Education Resources.
This activity is supported by an independent educational grant from Dexcom, Inc.

Share:

February 15, 2023
CGM Technology and Digital Health
Infographic

Click here to open the chart in a new window.

Share:

January 25, 2023
CGM Technology and Digital Health
CGM Innovations

A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.

Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.

1. Psavko S et al. JMIR Hum Factors 2022;9(4):42057
Learn More
Share:

January 18, 2023
Clinical Outcomes
Article / Publication

International diabetes experts recently collaborated to provide recommendations on how to optimize CGM-derived glucose data collection in clinical studies, including the specific glucose metrics and specific glucose metrics that should be evaluated. These consensus recommendations have been endorsed by key professional organizations, including the American Association of Clinical Endocrinologists, the American Diabetes Association, the Association of Diabetes Care and Education Specialists, Diabetes India, the European Association for the Study of Diabetes, the International Society for Pediatric and Adolescent Diabetes, the Japanese Diabetes Society, and the Juvenile Diabetes Research Foundation. This recommended standardized approach to CGM data collection and reporting in clinical trials will encourage the use of uniform metrics and enhance the interpretability of CGM data. Managed care and payer professionals should note that these metrics offer a body of useful information beyond HbA1c to inform therapeutic and treatment decisions, particularly related to hypoglycemia, postprandial hyperglycemia, and glucose variability.

Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2023;11:42-57.

Learn More
Share:

January 18, 2023
Coverage and Benefit Design
Article / Publication

Pharmacy professionals and a payer representative convened an expert panel to connect available evidence and the panelists’ extensive experiences on the value of RT-CGM in improving patient quality of life. In addition, the panelists provided prac­tical approaches to bring awareness, accessibility, and the utility of rtCGM to positively impact patient quality of life in practical applications. Managed care and payer professionals will find these real-world insights useful in characterizing the value of RT-CGM in health plan populations when making coverage determinations.

Real-Time Continuous Glucose Monitoring: Timely Opportunities to Improve Quality of Life.” CGM Live Virtual Crossfire Series Recap. Part 2. Pharmacy Times Continuing Education. August 2021.

Learn More
Share:

January 18, 2023
Coverage and Benefit Design
Article / Publication

An expert panel composed of pharmacists and a payer professional discussed the value of RT-CGM and the role pharmacists and pharmacy technicians have in optimizing diabetes management. By making RT-CGM available to and allowing pharmacy professionals to work alongside patients, health care stakeholders can leverage the information offered by this technology to optimize diabetes management and mitigate disease impact. The panelists noted that coverage of RT-CGM through the pharmacy benefit facilitates access by allowing patients to fill their prescription directly at community pharmacies. The panelists’ insights are of use to managed care and payer professionals in determining optimal coverage policies for RT-CGM to improve outcomes among members with diabetes.

“Real-Time Continuous Glucose Monitoring: Implications for Pharmacists.” CGM Live Virtual Crossfire Series Recap. Part 1. Pharmacy Times Continuing Education. May 2021.

Learn More
Share: